Cantor Fitzgerald Reiterates “Overweight” Rating for Affimed (NASDAQ:AFMD)

Affimed (NASDAQ:AFMD)‘s stock had its “overweight” rating restated by investment analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday,Benzinga reports.

A number of other equities research analysts also recently weighed in on AFMD. Stifel Nicolaus reduced their target price on Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a report on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Affimed in a research note on Friday, November 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Affimed has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Affimed Trading Down 9.3 %

NASDAQ AFMD opened at $2.72 on Tuesday. The stock has a 50-day simple moving average of $3.43 and a 200 day simple moving average of $4.47. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 0.13. Affimed has a 12 month low of $2.72 and a 12 month high of $8.95.

Affimed (NASDAQ:AFMD) last posted its quarterly earnings data on Thursday, September 5th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.09). Affimed had a negative return on equity of 193.84% and a negative net margin of 7,836.26%. The firm had revenue of $0.17 million for the quarter, compared to analyst estimates of $1.67 million. On average, analysts expect that Affimed will post -4.25 earnings per share for the current fiscal year.

Institutional Trading of Affimed

Several large investors have recently modified their holdings of the business. Jane Street Group LLC purchased a new stake in shares of Affimed in the 3rd quarter worth approximately $44,000. Point72 Asset Management L.P. lifted its position in Affimed by 4.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after acquiring an additional 15,108 shares in the last quarter. FMR LLC lifted its holdings in shares of Affimed by 30.0% during the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 4,086 shares during the period. Intellectus Partners LLC lifted its holdings in shares of Affimed by 12.2% during the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after buying an additional 10,250 shares during the period. Finally, Choreo LLC bought a new position in shares of Affimed during the 2nd quarter valued at $54,000. 30.82% of the stock is owned by institutional investors.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.